Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances

Cartesian Therapeutics, Inc.

2026-Q1 EPS reported -$1.46 revenue$78,000

Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.
Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.
R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).
Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Cartesian Therapeutics, Inc. reported three months ended March 31, 2026 results: net income -39,200,000, EPS -1.46.

Period: three months ended March 31, 2026
Net income: -39,200,000
EPS: -1.46

Exact text from the filing

Net loss was $39.2 million, or $1.46 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2026, compared to net loss of $17.7 million, or $0.68 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-26-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.